SUMMARY

ABRAXANE威 Competitive Landscape in China (Late-Stage)

For albumin-bound paclitaxel, paclitaxel is bonded to albumin as a delivery vehicle, which has demonstrated higher
response rates and improved tolerability when compared with solvent-based formulations in patients with advanced

metastatic breat cancer and NSCLC. Paclitaxel is a kind of cytoskeletal interference drugs and stabilizes the microtubule

polymer and protects it from disassembly.

Products
(generic

name)

Products

(brand name)

Company

CDA Status

Lead

Indications

Reimbursement

U.S. Patent
Exclusivity

Generic
Versions

albumin-bound

paclitaxel

ABRAXANE威

Celgene,
BeiGene

Approved

(2008)

Breast cancer

albumin-bound

paclitaxel

albumin-bound

paclitaxel

albumin-bound

paclitaxel

albumin-bound

paclitaxel

albumin-bound

paclitaxel

albumin-bound

paclitaxel

NA

CSPC

Approved
(2018.2)

Breast cancer

NA

NA

Zhejiang

Hisun

ANDA review Breast cancer

Qilu

ANDA review Breast cancer

NA

Yangtze River ANDA review Breast cancer

NA

NA

Jiangsu
Kanghe

ANDA review Breast cancer

Hengrui

ANDA review Breast cancer

PRDL Category B:

Jiangsu, Hubei,
Fujian, Ningxia,

Hunan; CII:

Zhejiang, Shandong

PRDL Category B:

Jiangsu, Hubei,
Ningxia, Hunan;
CII: Shandong

NA

NA

NA

NA

NA

2022

See

below

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Abbreviations: PRDL = provincial reimbursement drug list; ANDA = abbreviated new drug application

— 10 —

